Investing carries serious risks, including partial or total loss of capital. Please read the Information Note and the Risk factors and login before investing.

Neutraceutical food patent company 1A

Tax Shelter
Equity Belgium 139 investors
Making industrial food cholesterol-friendly
Information Note Terms & Conditions
€1,000,000
Pre money valuation
33.3%
Equity offered
€209,000
Amount raised
€50,000
Committed by co-investors
4 days
Remaining
€50,000
Minimum target
418% funded

Coralie B

Dear Mr Thomas,
Please find below a summary review of Balance sheet (at 31st December 2020)
The main shareholders will be the founders of the company.
The patent will be the property of NFPC. The agreement is ongoing and will be signed before the creation of the company NFPC.

Balance Sheet - 31.12.2020 :
TOTAL Assets = € 183.800
composed of:
Intangible Assets € 160.000 (200.000 - first year depreciation)
Cash: € 23.800

TOTAL Liabilities = € 183.800
composed of :
Capital € 350.000
result of the year - € 183.306
Commercial debts € 17.106

If you need further explanation, please don't hesitate to contact me by email : coralie.brancart@normaphar.be

Thomas R

Thank you for your answer.

31/12/2020? So, you're speaking about the guidance for the end of 2020 then?

Thomas R

- How does your balance sheet look like? how many debts?
- Who are the biggest shareholders after this transaction?
- Will the patent effectively be the property of NFPC? Is their a concluded agreement on the sale of the patent for 200k?

Coralie B

Dear Olli B
Thanks for your question .

Our alimentary patent don't reduce cholesterol .
The innovation is :
That the patented ingredient included in the food will not give more cholesterol to the person.
For example : If you like butter... continue to eat butter without the cholesterol effects that butter normally gives when you eat it .
We haven't competitor on the market.

Guy W.

Olli B

How much the patent reduces the cholesterol? What are the main competing solutions and the competitiveness of the suggested patent against them?

Eric B

Who will own the IP related to the patents? Normaphar or NFPC? If Normaphar keeps it, under which conditions will NFPC be allowed to use the IP?

Coralie B

Dear Eric,
NFPC will own the IP.
NFPC will purchase the patent to Normaphar (200K€). This amount has been evaluated and certified by an external auditor.
If you need further explanation, please don't hesitate to contact me by email : coralie.brancart@normaphar.be